gabapentin has been researched along with Absence Seizure in 98 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)." | 9.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
| "To evaluate the comparative safety and adjunctive efficacy of pregabalin and gabapentin in reducing seizure frequency in patients with partial-onset seizures based on prestudy modeling showing superior efficacy for pregabalin." | 9.22 | Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. ( Almas, M; French, J; Friedman, D; Glue, P; Knapp, L; Pitman, V; Posner, HB; Yardi, N, 2016) |
| "To evaluate the long-term efficacy of gabapentin (GBP) and usefulness of measurement of the blood level for the observation of patients that have partial seizures." | 9.19 | The efficacy of gabapentin in children of partial seizures and the blood levels. ( Ishii, M; Iwasaki, T; Nonoda, Y, 2014) |
| " At our institution, new-onset seizures in children on chemotherapy are treated with gabapentin, a nonhepatic enzyme inducer." | 9.11 | Gabapentin to control seizures in children undergoing cancer treatment. ( Hunt, DL; Khan, RB; Thompson, SJ, 2004) |
| "Studies in patients with epilepsy undergoing telemetry evaluation for surgery have suggested that discontinuation of carbamazepine (CBZ) is associated with increased seizures." | 9.09 | Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial. ( DeToledo, JC; Garofalo, EA; Greiner, M; Lowe, MR; Ramsay, RE, 2000) |
| "The effect of gabapentin on cognition and quality of life (QoL) in patients with epilepsy was investigated using a controlled pre- and post-treatment design." | 9.08 | Effects of gabapentin on cognition and quality of life in patients with epilepsy. ( Emmers, E; Mortimore, C; Trimble, M, 1998) |
| "Gabapentin is widely approved as add-on therapy for epilepsy treatment for partial seizures with and without secondary generalization." | 9.08 | A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. ( Alexander, J; Anhut, H; Chadwick, DW; Garofalo, EA; Greiner, MJ; Murray, GH; Pierce, MW, 1998) |
| "This study evaluated the effect of androsterone (AND), a metabolite of testosterone, on the ability of selected classical and novel antiepileptic drugs to prevent seizures caused by maximal electroshock (MES), which may serve as an experimental model of human generalized tonic-clonic seizures in mice." | 7.91 | Effects of androsterone on the protective action of various antiepileptic drugs against maximal electroshock-induced seizures in mice. ( Aebisher, D; Bartusik-Aebisher, D; Buszewicz, G; Kołodziejczyk, P; Mróz, K; Mróz, T; Tutka, P; Łuszczki, JJ, 2019) |
| "Cannabidiol and cannabidiol-enriched products have recently attracted much attention as an add-on therapy for epilepsy, especially drug-resistant seizures." | 7.91 | Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. ( Nieoczym, D; Socała, K; Szafarz, M; Wlaź, P; Wyska, E, 2019) |
| "In a large cohort of older patients with a seizure disorder, pregabalin was not associated with an increased risk of heart failure relative to gabapentin." | 7.85 | Pregabalin and heart failure: A population-based study. ( Antoniou, T; Gomes, T; Ho, JM; Juurlink, DN; Luo, J; Macdonald, EM; Mamdani, MM, 2017) |
| "These data indicate that MSCs were superior to gabapentin in ameliorating PTZ-induced epileptogenesis and verified the potential use of MSCs in seizure control, motor and cognitive impairments, oxidative stress, and the impairing GABA level in experimentally induced epilepsy." | 7.80 | Effects of intravenous human umbilical cord blood mesenchymal stem cell therapy versus gabapentin in pentylenetetrazole-induced chronic epilepsy in rats. ( Essawy, SS; Ewais, MM; Mohammed, AS; Tawfik, MK, 2014) |
| "The lithium-pilocarpine model of epilepsy reproduces in rodents several features of human temporal lobe epilepsy, by inducing an acute status epilepticus (SE) followed by a latency period." | 7.79 | Gabapentin administration reduces reactive gliosis and neurodegeneration after pilocarpine-induced status epilepticus. ( Angelo, MF; Lukin, J; Ramos, AJ; Rossi, AR; Villarreal, A, 2013) |
| "To evaluate the effects of high-frequency electrical stimulation (HFS) in both ventral hippocampi, alone and combined with a subeffective dose of antiepileptic drugs, during the status epilepticus (SE) induced by lithium-pilocarpine (LP)." | 7.76 | Antiepileptic drugs combined with high-frequency electrical stimulation in the ventral hippocampus modify pilocarpine-induced status epilepticus in rats. ( Alcantara-Gonzalez, D; Cuellar-Herrera, M; Neri-Bazan, L; Peña, F; Rocha, L, 2010) |
| "This work was designed to study the influence of drugs during seizures and status epilepticus (SE) induced by pilocarpine and mortality in adult rats." | 7.74 | Study pharmacologic of the GABAergic and glutamatergic drugs on seizures and status epilepticus induced by pilocarpine in adult Wistar rats. ( Assis, MA; Fonteles, MM; Freitas, RL; Freitas, RM; Pereira, MB; Silva, RF; Takahashi, RN, 2007) |
| "This work was designed to study the influence of drugs during seizures and status epilepticus (SE) induced by pilocarpine and mortality in adult rats." | 7.73 | Effect of gabaergic, glutamatergic, antipsychotic and antidepressant drugs on pilocarpine-induced seizures and status epilepticus. ( Fonteles, MM; Freitas, RM; Sousa, FC; Viana, GS, 2006) |
| "To assess whether there is a change in seizure activity in dogs with refractory epilepsy that are receiving appropriate doses of phenobarbitone and/or potassium bromide, when gabapentin is added to the therapeutic regimen." | 7.73 | Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent. ( Govendir, M; Malik, R; Perkins, M, 2005) |
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 7.69 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| "Gabapentin monotherapy was useful and safe for late poststroke ES." | 6.70 | Gabapentin in late-onset poststroke seizures. ( Alvarez-Sabín, J; Codina, A; Molina, CA; Montaner, J; Padró, L; Quintana, M; Rovira, R, 2002) |
| "Gabapentin (GBP) is a non-protein-bound gamma amino acid which is not subjected to metabolic degradation in man." | 6.68 | Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures. ( Ben-Menachem, E; Hamberger, A; Hedner, T; Persson, LI; Söderfelt, B, 1995) |
| "Pentylenetetrazole (PTZ) was used to induce convulsions in rats through elevating seizure stages, releasing neuroinflammatory mediators and reducing excitatory amino acid transporter 2 (EAAT 2) and γ-aminobutyric acid (GABA) brain contents." | 5.62 | Single step nanospray drying preparation technique of gabapentin-loaded nanoparticles-mediated brain delivery for effective treatment of PTZ-induced seizures. ( Elhabak, M; Salama, AAA; Salama, AH, 2021) |
| "Gabapentin is an antiepileptic that is used to manage neuropathic pain." | 5.46 | Gabapentin-Induced Bullous Pemphigoid. ( Dufresne, F; Flamm, A; Sachdev, S, 2017) |
| "In this study, we evaluated the dose-response efficacy of levetiracetam (12." | 5.46 | Combination therapy of levetiracetam and gabapentin against nonconvulsive seizures induced by penetrating traumatic brain injury. ( Cao, Y; Liao, Z; Lu, XM; Mountney, A; Shear, DA; Tortella, FC, 2017) |
| "Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)." | 5.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
| "Acute seizure activity was behaviorally scored and hemispheric brain atrophy measured." | 5.35 | Gabapentin neuroprotection and seizure suppression in immature mouse brain ischemia. ( Comi, AM; Johnston, MV; Kadam, SD; Mulholland, JD; Traa, BS, 2008) |
| "Seizures were detected by continuous electroencephalographic monitoring for 24 h following permanent middle cerebral artery occlusion (MCAo)." | 5.33 | Evaluation of gabapentin and ethosuximide for treatment of acute nonconvulsive seizures following ischemic brain injury in rats. ( Bautista, CC; Chen, RW; Dave, JR; Hartings, JA; Lu, XC; Tortella, FC; Williams, AJ, 2006) |
| "Gabapentin was also effective against two other bs mutants, bangsenseless(1) and slamdance(iso7." | 5.32 | Treatment with the antiepileptic drugs phenytoin and gabapentin ameliorates seizure and paralysis of Drosophila bang-sensitive mutants. ( Feeney, L; Jacobs, B; McKeever, C; Reynolds, ER; Rojahn, E; Stauffer, EA, 2004) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 5.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "Seizures associated with intracranial neoplasms are occasionally refractory to conventional anti-epileptic drugs." | 5.29 | Add-on gabapentin for refractory seizures in patients with brain tumours. ( Perry, JR; Sawka, C, 1996) |
| "To evaluate the comparative safety and adjunctive efficacy of pregabalin and gabapentin in reducing seizure frequency in patients with partial-onset seizures based on prestudy modeling showing superior efficacy for pregabalin." | 5.22 | Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. ( Almas, M; French, J; Friedman, D; Glue, P; Knapp, L; Pitman, V; Posner, HB; Yardi, N, 2016) |
| "To evaluate the long-term efficacy of gabapentin (GBP) and usefulness of measurement of the blood level for the observation of patients that have partial seizures." | 5.19 | The efficacy of gabapentin in children of partial seizures and the blood levels. ( Ishii, M; Iwasaki, T; Nonoda, Y, 2014) |
| " At our institution, new-onset seizures in children on chemotherapy are treated with gabapentin, a nonhepatic enzyme inducer." | 5.11 | Gabapentin to control seizures in children undergoing cancer treatment. ( Hunt, DL; Khan, RB; Thompson, SJ, 2004) |
| "Studies in patients with epilepsy undergoing telemetry evaluation for surgery have suggested that discontinuation of carbamazepine (CBZ) is associated with increased seizures." | 5.09 | Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial. ( DeToledo, JC; Garofalo, EA; Greiner, M; Lowe, MR; Ramsay, RE, 2000) |
| "The aim of the study was to find out the percentage of patients with localization-related epilepsy achieving complete seizure control with gabapentin (GBP) add-on therapy." | 5.09 | Gabapentin add-on treatment: how many patients become seizure-free? An open-label multicenter study. ( Elger, CE; Mayer, T; Schütte, W; Wolf, P, 1999) |
| "Gabapentin is widely approved as add-on therapy for epilepsy treatment for partial seizures with and without secondary generalization." | 5.08 | A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. ( Alexander, J; Anhut, H; Chadwick, DW; Garofalo, EA; Greiner, MJ; Murray, GH; Pierce, MW, 1998) |
| "The effect of gabapentin on cognition and quality of life (QoL) in patients with epilepsy was investigated using a controlled pre- and post-treatment design." | 5.08 | Effects of gabapentin on cognition and quality of life in patients with epilepsy. ( Emmers, E; Mortimore, C; Trimble, M, 1998) |
| "Fifty patients with refractory partial seizures took part in a prospective, observational study of adjuvant gabapentin (GBP) in increasing doses." | 5.08 | High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. ( Brodie, MJ; Forrest, G; Sills, GJ; Wilson, EA, 1998) |
| "Clinically significant side effects of the new anticonvulsants, such as metabolic acidosis from topiramate, autoimmune reactions from lamotrigine, hyponatremia from oxcarbazepine, or psychosis from levitiracetam can cause serious morbidity and mortality if unrecognized." | 4.86 | Emergent complications of the newer anticonvulsants. ( Dang, CV; Nelson, L; Wade, JF; Wasserberger, J, 2010) |
| "Since 1994, three new antiepileptic drugs, felbamate, lamotrigene, and gabapentin, have been released for the treatment of epilepsy." | 4.79 | A review of the newer antiepileptic drugs and the ketogenic diet. ( Barron, TF; Hunt, SL, 1997) |
| "Three new antiepileptic drugs--vigabatrin, gabapentin, and lamotrigine--provide alternatives in the management of older patients with refractory partial seizures." | 4.79 | Seizure control: how to use the new antiepileptic drugs in older patients. ( Haider, A; Haider, S; Tuchek, JM, 1996) |
| "Cannabidiol and cannabidiol-enriched products have recently attracted much attention as an add-on therapy for epilepsy, especially drug-resistant seizures." | 3.91 | Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. ( Nieoczym, D; Socała, K; Szafarz, M; Wlaź, P; Wyska, E, 2019) |
| "This study evaluated the effect of androsterone (AND), a metabolite of testosterone, on the ability of selected classical and novel antiepileptic drugs to prevent seizures caused by maximal electroshock (MES), which may serve as an experimental model of human generalized tonic-clonic seizures in mice." | 3.91 | Effects of androsterone on the protective action of various antiepileptic drugs against maximal electroshock-induced seizures in mice. ( Aebisher, D; Bartusik-Aebisher, D; Buszewicz, G; Kołodziejczyk, P; Mróz, K; Mróz, T; Tutka, P; Łuszczki, JJ, 2019) |
| "In a large cohort of older patients with a seizure disorder, pregabalin was not associated with an increased risk of heart failure relative to gabapentin." | 3.85 | Pregabalin and heart failure: A population-based study. ( Antoniou, T; Gomes, T; Ho, JM; Juurlink, DN; Luo, J; Macdonald, EM; Mamdani, MM, 2017) |
| "These data indicate that MSCs were superior to gabapentin in ameliorating PTZ-induced epileptogenesis and verified the potential use of MSCs in seizure control, motor and cognitive impairments, oxidative stress, and the impairing GABA level in experimentally induced epilepsy." | 3.80 | Effects of intravenous human umbilical cord blood mesenchymal stem cell therapy versus gabapentin in pentylenetetrazole-induced chronic epilepsy in rats. ( Essawy, SS; Ewais, MM; Mohammed, AS; Tawfik, MK, 2014) |
| " Our data have demonstrated that pentylenetetrazole (PTZ)-induced seizures did not alter ATP, ADP, and AMP hydrolysis in brain membrane fractions." | 3.79 | Antiepileptic drugs prevent changes in adenosine deamination during acute seizure episodes in adult zebrafish. ( Bogo, MR; Bonan, CD; Nery, LR; Piato, AL; Schaefer, IC; Siebel, AM, 2013) |
| "The lithium-pilocarpine model of epilepsy reproduces in rodents several features of human temporal lobe epilepsy, by inducing an acute status epilepticus (SE) followed by a latency period." | 3.79 | Gabapentin administration reduces reactive gliosis and neurodegeneration after pilocarpine-induced status epilepticus. ( Angelo, MF; Lukin, J; Ramos, AJ; Rossi, AR; Villarreal, A, 2013) |
| "The present study was performed to investigate whether or not carvedilol (a beta-adrenoreceptor antagonist) potentiates the anticonvulsive activity of gabapentin against ICES (Increasing current electroshock) and PTZ (Pentylenetetrazole) induced seizures in mice." | 3.77 | Influence of carvedilol on anticonvulsant effect of gabapentin. ( Goel, A; Goel, R; Kumar, Y, 2011) |
| "Gabapentin is an antiepileptic drug used as adjunct therapy in the treatment of seizures." | 3.77 | Performance characteristics of the ARK diagnostics gabapentin immunoassay. ( Anderson, BL; Johnson-Davis, KL; Juenke, JM; McMillin, GA; Wienhoff, KA, 2011) |
| "To evaluate the effects of high-frequency electrical stimulation (HFS) in both ventral hippocampi, alone and combined with a subeffective dose of antiepileptic drugs, during the status epilepticus (SE) induced by lithium-pilocarpine (LP)." | 3.76 | Antiepileptic drugs combined with high-frequency electrical stimulation in the ventral hippocampus modify pilocarpine-induced status epilepticus in rats. ( Alcantara-Gonzalez, D; Cuellar-Herrera, M; Neri-Bazan, L; Peña, F; Rocha, L, 2010) |
| "To characterize the interactions between levetiracetam and the antiepileptic drugs gabapentin, tiagabine, and vigabatrin in suppressing pentylenetetrazole-induced clonic seizures in mice, type II isobolographic analysis was used." | 3.75 | Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis. ( Andres-Mach, MM; Czuczwar, SJ; Dudra-Jastrzebska, M; Luszczki, JJ; Patsalos, PN; Ratnaraj, N; Sielski, M, 2009) |
| " Isobolographic analysis was used in two mouse experimental models of epilepsy: the maximal electroshock seizure threshold test and pentylenetetrazole-induced seizures." | 3.74 | Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. ( Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2008) |
| "The objective of this study was to characterize the anticonvulsant and acute adverse-effect potentials of topiramate (TPM) and gabapentin (GBP)-two second-generation antiepileptic drugs administered alone and in combination in the maximal electroshock (MES)-induced seizures and chimney test in mice." | 3.74 | Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. ( Luszczki, JJ, 2007) |
| "We investigated efficacy of prolonged intraventricular gabapentin (GBP) infusion in the rat flurothyl epilepsy model." | 3.74 | Intraventricular administration of gabapentin in the rat increases flurothyl seizure threshold. ( Fisher, RS; Kraus, AC; Oommen, J, 2007) |
| "This work was designed to study the influence of drugs during seizures and status epilepticus (SE) induced by pilocarpine and mortality in adult rats." | 3.74 | Study pharmacologic of the GABAergic and glutamatergic drugs on seizures and status epilepticus induced by pilocarpine in adult Wistar rats. ( Assis, MA; Fonteles, MM; Freitas, RL; Freitas, RM; Pereira, MB; Silva, RF; Takahashi, RN, 2007) |
| "To assess whether there is a change in seizure activity in dogs with refractory epilepsy that are receiving appropriate doses of phenobarbitone and/or potassium bromide, when gabapentin is added to the therapeutic regimen." | 3.73 | Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent. ( Govendir, M; Malik, R; Perkins, M, 2005) |
| " Anticonvulsant and acute neurotoxic adverse effect profiles of combinations of GBP and TGB with other AEDs at fixed ratios of 1:3, 1:1 and 3:1 were investigated in pentylenetetrazole (PTZ)-induced seizures and the chimney test (as a measure of motor impairment) in mice so as to identify optimal combinations." | 3.73 | Isobolographic characterisation of interactions among selected newer antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model. ( Czuczwar, SJ; Luszczki, JJ, 2005) |
| "This work was designed to study the influence of drugs during seizures and status epilepticus (SE) induced by pilocarpine and mortality in adult rats." | 3.73 | Effect of gabaergic, glutamatergic, antipsychotic and antidepressant drugs on pilocarpine-induced seizures and status epilepticus. ( Fonteles, MM; Freitas, RM; Sousa, FC; Viana, GS, 2006) |
| "Gabapentin (GBP) is a gamma-aminobutyric acid analog effective in the treatment of seizures." | 3.71 | Long-term regulation of voltage-gated Ca(2+) channels by gabapentin. ( Campbell, KP; Felix, R; Kang, MG, 2002) |
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 3.69 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| "The effects of three new antiepileptic drugs (felbamate, lamotrigine and gabapentin) on the parameters of seizure initiation and termination in one model of reverberatory seizures in the hippocampal-parahippocampal loop in urethane-anesthetized rats were determined." | 3.69 | Effects of felbamate, gabapentin and lamotrigine on seizure parameters and excitability in the rat hippocampus. ( Stringer, JL; Xiong, ZQ, 1997) |
| "Epilepsy is a chronic disease of the central nervous system characterized by recurrent epileptic seizures." | 3.01 | Second Generation of Antiepileptic Drugs and Oxidative Stress. ( Czuczwar, SJ; Kamieniak, M; Kośmider, K; Miziak, B, 2023) |
| "The phenytoin treatment causes cerebellar defect and anemia." | 2.82 | The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches. ( Agrawal, M; Dhurandhar, Y; Panda, SP, 2022) |
| "Gabapentin monotherapy was useful and safe for late poststroke ES." | 2.70 | Gabapentin in late-onset poststroke seizures. ( Alvarez-Sabín, J; Codina, A; Molina, CA; Montaner, J; Padró, L; Quintana, M; Rovira, R, 2002) |
| "Gabapentin (GBP) is a non-protein-bound gamma amino acid which is not subjected to metabolic degradation in man." | 2.68 | Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures. ( Ben-Menachem, E; Hamberger, A; Hedner, T; Persson, LI; Söderfelt, B, 1995) |
| "28), indicating a dose-response relationship." | 2.61 | Pregabalin add-on for drug-resistant focal epilepsy. ( Bresnahan, R; Hemming, K; Marson, AG; Panebianco, M, 2019) |
| "The aim of this review was to evaluate current literature for dosing recommendations for the use of antiepileptic medications in patients receiving renal replacement therapy (RRT)." | 2.53 | Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. ( Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016) |
| "Therefore, the optimal seizure management by antiepileptic drugs (AEDs) in this patient category is essentially unsure." | 2.43 | Optimal seizure management in brain tumor patients. ( van Breemen, MS; Vecht, CJ, 2005) |
| "Gabapentin was originally designed as an anti-convulsant gamma-aminobutyric acid (GABA) mimetic capable of crossing the blood-brain barrier." | 2.42 | Cellular and molecular action of the putative GABA-mimetic, gabapentin. ( Chung, FZ; Gonzalez, MI; Lee, K; Maneuf, YP; Pinnock, RD; Sutton, KS, 2003) |
| "Successful treatment of seizure disorders in small animals requires proper patient assessment, understanding the principles of antiepileptic drug (AED) therapy, designing a strategy for pharmacotherapy, and plans for emergency treatment." | 2.40 | Antiepileptic drug therapy. ( Podell, M, 1998) |
| "Successful control of seizures with anticonvulsant drugs reflects a balance in achieving seizure control while minimizing undesirable drug side effects." | 2.40 | Anticonvulsant therapy in small animals. ( Boothe, DM, 1998) |
| "For residents without seizures, 85% of ASMs prescribed have alternative indications for mood or pain symptoms, and large gains in gabapentin and modest but significant increases in valproate, lamotrigine, carbamazepine, and topiramate prescribing were detected." | 1.91 | Trends in Antiseizure Medication Prescribing Among Nursing Home Residents With and Without a Seizure Diagnosis. ( Kerns, JW; Richards, A; Sabo, RT; Winter, JD; Winter, KM, 2023) |
| "aspiration; children; dystonia; epilepsy; pneumonia." | 1.72 | Status Dystonicus with Atypical Presentation in Developmentally Delay Child: A Case Report. ( Dahal, S; Khati, N; Maharjan, G; Yadav, P; Yadav, SK, 2022) |
| "There have been several reports that switching formulations of antiseizure medications (ASMs) has been associated with a deterioration of seizure control, seizure relapse or increased adverse effects." | 1.72 | Analyzing excipient-related adverse events in antiseizure drug formulations. ( Ionova, Y; Peterson, T; Wilson, L, 2022) |
| "Pentylenetetrazole (PTZ) was used to induce convulsions in rats through elevating seizure stages, releasing neuroinflammatory mediators and reducing excitatory amino acid transporter 2 (EAAT 2) and γ-aminobutyric acid (GABA) brain contents." | 1.62 | Single step nanospray drying preparation technique of gabapentin-loaded nanoparticles-mediated brain delivery for effective treatment of PTZ-induced seizures. ( Elhabak, M; Salama, AAA; Salama, AH, 2021) |
| "Cases with EoE with a psychiatric diagnosis were more likely to be women, white, and 18 years or older and to have a longer symptom duration before diagnosis." | 1.56 | Psychiatric Comorbidities and Psychiatric Medication Use Are Highly Prevalent in Patients With Eosinophilic Esophagitis and Associate With Clinical Presentation. ( Corder, SR; Dellon, ES; Eluri, S; Kim, E; Reed, CC; Sanders, E; Tappata, M, 2020) |
| "The predominant seizure types in NLLOE were focal to bilateral tonic-clonic seizures (30%) as well as focal onset impaired awareness motor seizures (IAMS) (22%) and focal onset impaired awareness nonmotor seizures (IANMS) (22%)." | 1.51 | Nonlesional late-onset epilepsy: Semiology, EEG, cerebrospinal fluid, and seizure outcome characteristics. ( Flöel, A; Hamann, L; Süße, M; von Podewils, F, 2019) |
| " Results of the study indicate that 1) Early SIS could be considered as an animal model of psychosocial stress to investigate the psychiatric comorbidities in seizure disorders, 2) Chronic administration of low dose GBP prevented the shaping of behavioral abnormalities in adulthood, 3) Chronic administration of low dose GBP produced no negative behavioral effects in socially conditioned mice suggesting the safety of the drug, 4) Gabapentin at low doses may be considered as an agent for management of epilepsy in individuals with psychiatric comorbidities." | 1.46 | Protective effects of gabapentin against the seizure susceptibility and comorbid behavioral abnormalities in the early socially isolated mice. ( Amini-Khoei, H; Amiri, S; Ghazi-Khansari, M; Haj-Mirzaian, A; Mohsenzadeh, A; Olson, CO; Rahimi-Balaei, M; Rastegar, M; Razmi, A; Shirzadian, A; Zarrindast, MR, 2017) |
| "In this study, we evaluated the dose-response efficacy of levetiracetam (12." | 1.46 | Combination therapy of levetiracetam and gabapentin against nonconvulsive seizures induced by penetrating traumatic brain injury. ( Cao, Y; Liao, Z; Lu, XM; Mountney, A; Shear, DA; Tortella, FC, 2017) |
| "Gabapentin is an antiepileptic that is used to manage neuropathic pain." | 1.46 | Gabapentin-Induced Bullous Pemphigoid. ( Dufresne, F; Flamm, A; Sachdev, S, 2017) |
| "Tonic hind limb extension (seizure activity) was evoked in adult male albino Swiss mice by a current (sine-wave, 25 mA, 500 V, 50 Hz, 0." | 1.38 | Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis. ( Filip, D; Florek-Luszczki, M; Luszczki, JJ, 2012) |
| "Seizures were assessed in terms of a composite seizure severity score (SSS), time of the onset of straub-like tail, onset of jerky movements of whole body, convulsions and death." | 1.37 | Amisulpride-induced seizurogenic effect: a potential role of opioid receptor-linked transduction systems. ( Chand, P; Rehni, AK; Singh, TG, 2011) |
| "Seizures were assessed in terms of the time latency of the onset of Straub's tail phenomenon, onset of jerky movements of whole body, convulsions and death." | 1.35 | Tramadol-induced seizurogenic effect: a possible role of opioid-dependent gamma-aminobutyric acid inhibitory pathway. ( Kumar, M; Rehni, AK; Singh, I, 2008) |
| "Acute seizure activity was behaviorally scored and hemispheric brain atrophy measured." | 1.35 | Gabapentin neuroprotection and seizure suppression in immature mouse brain ischemia. ( Comi, AM; Johnston, MV; Kadam, SD; Mulholland, JD; Traa, BS, 2008) |
| " Additionally, the effects of acute and chronic administration of aminophylline on the adverse effect potential of gabapentin in terms of motor coordination impairment were assessed in the chimney test." | 1.34 | Influence of aminophylline on the anticonvulsive action of gabapentin in the mouse maximal electroshock seizure threshold model. ( Czuczwar, SJ; Jankiewicz, K; Jankiewicz, M; Luszczki, JJ, 2007) |
| "Seizures were detected by continuous electroencephalographic monitoring for 24 h following permanent middle cerebral artery occlusion (MCAo)." | 1.33 | Evaluation of gabapentin and ethosuximide for treatment of acute nonconvulsive seizures following ischemic brain injury in rats. ( Bautista, CC; Chen, RW; Dave, JR; Hartings, JA; Lu, XC; Tortella, FC; Williams, AJ, 2006) |
| "Nonconvulsive seizures (NCSs) after traumatic and ischemic brain injury are often refractory to antiepileptic drug therapy and are associated with a decline in patient outcome." | 1.32 | Antiepileptic drug treatment of nonconvulsive seizures induced by experimental focal brain ischemia. ( Hartings, JA; Lu, XM; Moreton, JE; Tortella, FC; Williams, AJ, 2004) |
| "Gabapentin was also effective against two other bs mutants, bangsenseless(1) and slamdance(iso7." | 1.32 | Treatment with the antiepileptic drugs phenytoin and gabapentin ameliorates seizure and paralysis of Drosophila bang-sensitive mutants. ( Feeney, L; Jacobs, B; McKeever, C; Reynolds, ER; Rojahn, E; Stauffer, EA, 2004) |
| "When the threshold for secondary generalized seizures (GST) was determined in addition to ADT, gabapentin and levetiracetam strikingly increased this threshold compared to predrug control." | 1.31 | Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats. ( Ebert, U; Löscher, W; Reissmüller, E, 2000) |
| "Electroconvulsions were produced by means of an alternating current (ear-clip electrodes, 0." | 1.31 | Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. ( Borowicz, KK; Czuczwar, SJ; Luszczki, J; Swiader, M, 2002) |
| "Gabapentin has been shown to reduce paired-pulse inhibition in the dentate gyrus of the urethane-anesthetized rat and has been shown to block calcium channels, but its not known how these possible mechanisms relate to its antiepileptic effect." | 1.31 | The effects of gabapentin in the rat hippocampus are mimicked by two structural analogs, but not by nimodipine. ( Stringer, JL; Taylor, CP, 2000) |
| "Kainic acid (KA) was administered to rats on postnatal day (P) 35." | 1.31 | Anticonvulsant action and long-term effects of gabapentin in the immature brain. ( Bolanos, AR; Cilio, MR; Holmes, GL; Liu, Z; Mikati, MA; Schmid, R; Stafstrom, CE; Yang, Y, 2001) |
| "Kindled seizures were produced on day 16 of life by repeatedly applying an electrical current stimulus to the amygdala electrode." | 1.31 | Anticonvulsant efficacy of gabapentin on kindling in the immature brain. ( Lado, FA; Moshé, SL; Sperber, EF, 2001) |
| " Both effects exhibited a tendency to a U-shaped dose-response curve." | 1.30 | Anticonvulsant action of gabapentin during postnatal development in rats. ( Haugvicová, R; Mares, P, 1997) |
| "When information became available on aplastic anemia and hepatotoxicity associated with felbamate, all patients were advised to taper their felbamate dosage over approximately 2 weeks." | 1.30 | Increased seizure frequency associated with felbamate withdrawal in adults. ( Privitera, M; Shukla, R; Welty, TE, 1998) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 1.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "Gabapentin dose-dependently attenuated myoclonus in posthypoxic rats for more than 3 h." | 1.29 | Antimyoclonic effect of gabapentin in a posthypoxic animal model of myoclonus. ( Kanthasamy, AG; Truong, DD; Vu, TQ; Yun, RJ, 1996) |
| "Seizures associated with intracranial neoplasms are occasionally refractory to conventional anti-epileptic drugs." | 1.29 | Add-on gabapentin for refractory seizures in patients with brain tumours. ( Perry, JR; Sawka, C, 1996) |
| "after seizure induction than for those who received the same field over the left hemisphere or that had been exposed to reference conditions." | 1.29 | Long-term consequences of subtle stimuli during the first twenty-four hours of seizure-induced brain injury. ( Cook, LL; Persinger, MA, 1996) |
| "Gabapentin was administered at a dose of 23 mg/kg i." | 1.28 | Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. ( Hönack, D; Löscher, W; Taylor, CP, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 27 (27.55) | 18.2507 |
| 2000's | 33 (33.67) | 29.6817 |
| 2010's | 28 (28.57) | 24.3611 |
| 2020's | 10 (10.20) | 2.80 |
| Authors | Studies |
|---|---|
| Silverman, RB | 1 |
| Andruszkiewicz, R | 1 |
| Nanavati, SM | 1 |
| Taylor, CP | 3 |
| Vartanian, MG | 1 |
| Gitto, R | 1 |
| Pagano, B | 1 |
| Citraro, R | 1 |
| Scicchitano, F | 1 |
| De Sarro, G | 2 |
| Chimirri, A | 1 |
| Tripathi, L | 1 |
| Kumar, P | 1 |
| Chalasani, N | 1 |
| Bonkovsky, HL | 1 |
| Stine, JG | 1 |
| Gu, J | 1 |
| Barnhart, H | 1 |
| Jacobsen, E | 1 |
| Björnsson, E | 1 |
| Fontana, RJ | 1 |
| Kleiner, DE | 1 |
| Hoofnagle, JH | 1 |
| Ionova, Y | 1 |
| Peterson, T | 1 |
| Wilson, L | 1 |
| Panda, SP | 1 |
| Dhurandhar, Y | 1 |
| Agrawal, M | 1 |
| Yadav, SK | 1 |
| Yadav, P | 1 |
| Maharjan, G | 1 |
| Dahal, S | 1 |
| Khati, N | 1 |
| Kośmider, K | 1 |
| Kamieniak, M | 1 |
| Czuczwar, SJ | 11 |
| Miziak, B | 1 |
| Ziganshina, LE | 1 |
| Abakumova, T | 1 |
| Hoyle, CHV | 1 |
| Winter, JD | 1 |
| Kerns, JW | 1 |
| Winter, KM | 1 |
| Richards, A | 1 |
| Sabo, RT | 1 |
| Reed, CC | 1 |
| Corder, SR | 1 |
| Kim, E | 1 |
| Sanders, E | 1 |
| Tappata, M | 1 |
| Eluri, S | 1 |
| Dellon, ES | 1 |
| Luszczki, JJ | 10 |
| Panasiuk, A | 1 |
| Zagaja, M | 1 |
| Karwan, S | 1 |
| Bojar, H | 1 |
| Plewa, Z | 1 |
| Florek-Łuszczki, M | 1 |
| Salama, AH | 1 |
| Salama, AAA | 1 |
| Elhabak, M | 1 |
| Lu, XM | 2 |
| Cao, Y | 1 |
| Mountney, A | 1 |
| Liao, Z | 1 |
| Shear, DA | 1 |
| Tortella, FC | 3 |
| Ho, JM | 1 |
| Macdonald, EM | 1 |
| Luo, J | 1 |
| Gomes, T | 1 |
| Antoniou, T | 1 |
| Mamdani, MM | 1 |
| Juurlink, DN | 1 |
| Süße, M | 1 |
| Hamann, L | 1 |
| Flöel, A | 1 |
| von Podewils, F | 1 |
| Tutka, P | 1 |
| Mróz, K | 1 |
| Mróz, T | 1 |
| Buszewicz, G | 1 |
| Aebisher, D | 1 |
| Bartusik-Aebisher, D | 1 |
| Kołodziejczyk, P | 1 |
| Łuszczki, JJ | 2 |
| Panebianco, M | 1 |
| Bresnahan, R | 1 |
| Hemming, K | 1 |
| Marson, AG | 1 |
| Socała, K | 2 |
| Wyska, E | 1 |
| Szafarz, M | 1 |
| Nieoczym, D | 2 |
| Wlaź, P | 2 |
| Banote, RK | 1 |
| Koutarapu, S | 1 |
| Chennubhotla, KS | 1 |
| Chatti, K | 1 |
| Kulkarni, P | 1 |
| Lukawski, K | 1 |
| Janowska, A | 1 |
| Jakubus, T | 1 |
| Raszewski, G | 1 |
| Nonoda, Y | 1 |
| Iwasaki, T | 1 |
| Ishii, M | 1 |
| Belozertsev, IuA | 1 |
| Zapol'skaia, IuA | 1 |
| Belozertsev, FIu | 1 |
| Iuntsev, SV | 1 |
| Rossi, AR | 1 |
| Angelo, MF | 1 |
| Villarreal, A | 1 |
| Lukin, J | 1 |
| Ramos, AJ | 1 |
| Wilson, B | 1 |
| Lavanya, Y | 1 |
| Priyadarshini, SR | 1 |
| Ramasamy, M | 1 |
| Jenita, JL | 1 |
| Mohammed, AS | 1 |
| Ewais, MM | 1 |
| Tawfik, MK | 1 |
| Essawy, SS | 1 |
| Jargiełło-Baszak, M | 1 |
| Chrościńska-Krawczyk, M | 1 |
| Andres-Mach, M | 1 |
| French, J | 1 |
| Glue, P | 1 |
| Friedman, D | 1 |
| Almas, M | 1 |
| Yardi, N | 1 |
| Knapp, L | 1 |
| Pitman, V | 1 |
| Posner, HB | 1 |
| Smetana, KS | 1 |
| Cook, AM | 1 |
| Bastin, ML | 1 |
| Oyler, DR | 1 |
| Amiri, S | 1 |
| Haj-Mirzaian, A | 1 |
| Amini-Khoei, H | 1 |
| Razmi, A | 1 |
| Shirzadian, A | 1 |
| Rahimi-Balaei, M | 1 |
| Olson, CO | 1 |
| Mohsenzadeh, A | 1 |
| Rastegar, M | 1 |
| Zarrindast, MR | 1 |
| Ghazi-Khansari, M | 1 |
| Flamm, A | 1 |
| Sachdev, S | 1 |
| Dufresne, F | 1 |
| Rehni, AK | 2 |
| Singh, I | 1 |
| Kumar, M | 1 |
| Ratnaraj, N | 2 |
| Patsalos, PN | 2 |
| Wade, JF | 1 |
| Dang, CV | 1 |
| Nelson, L | 1 |
| Wasserberger, J | 1 |
| Fourcade, G | 1 |
| Roubertie, A | 1 |
| Doummar, D | 1 |
| Vidailhet, M | 1 |
| Labauge, P | 1 |
| Dudra-Jastrzebska, M | 1 |
| Andres-Mach, MM | 1 |
| Sielski, M | 1 |
| Czubak, A | 1 |
| Nowakowska, E | 1 |
| Kus, K | 1 |
| Sadowski, C | 1 |
| Matschay, A | 1 |
| Cuellar-Herrera, M | 1 |
| Peña, F | 1 |
| Alcantara-Gonzalez, D | 1 |
| Neri-Bazan, L | 1 |
| Rocha, L | 1 |
| Singh, TG | 1 |
| Chand, P | 1 |
| Vohora, D | 1 |
| Khanam, R | 1 |
| Pal, SN | 1 |
| Pillai, KK | 1 |
| Juenke, JM | 1 |
| Wienhoff, KA | 1 |
| Anderson, BL | 1 |
| McMillin, GA | 1 |
| Johnson-Davis, KL | 1 |
| Filip, D | 1 |
| Florek-Luszczki, M | 1 |
| Goel, R | 1 |
| Goel, A | 1 |
| Kumar, Y | 1 |
| Siebel, AM | 1 |
| Piato, AL | 1 |
| Schaefer, IC | 1 |
| Nery, LR | 1 |
| Bogo, MR | 1 |
| Bonan, CD | 1 |
| Borowicz, KK | 1 |
| Swiader, M | 1 |
| Luszczki, J | 1 |
| Kang, MG | 1 |
| Felix, R | 1 |
| Campbell, KP | 1 |
| Alvarez-Sabín, J | 1 |
| Montaner, J | 1 |
| Padró, L | 1 |
| Molina, CA | 1 |
| Rovira, R | 1 |
| Codina, A | 1 |
| Quintana, M | 1 |
| Zhang, ZJ | 1 |
| Russell, S | 1 |
| Obeng, K | 1 |
| Postma, T | 1 |
| Obrocea, G | 1 |
| Weiss, SR | 1 |
| Post, RM | 1 |
| Maneuf, YP | 1 |
| Gonzalez, MI | 1 |
| Sutton, KS | 1 |
| Chung, FZ | 1 |
| Pinnock, RD | 1 |
| Lee, K | 1 |
| Reynolds, ER | 1 |
| Stauffer, EA | 1 |
| Feeney, L | 1 |
| Rojahn, E | 1 |
| Jacobs, B | 1 |
| McKeever, C | 1 |
| Khan, RB | 1 |
| Hunt, DL | 1 |
| Thompson, SJ | 1 |
| Williams, AJ | 2 |
| Moreton, JE | 1 |
| Hartings, JA | 2 |
| van Breemen, MS | 1 |
| Vecht, CJ | 1 |
| Andres, MM | 1 |
| Govendir, M | 1 |
| Perkins, M | 1 |
| Malik, R | 1 |
| Bautista, CC | 1 |
| Chen, RW | 1 |
| Dave, JR | 1 |
| Lu, XC | 1 |
| Freitas, RM | 2 |
| Sousa, FC | 1 |
| Viana, GS | 1 |
| Fonteles, MM | 2 |
| Oommen, J | 1 |
| Kraus, AC | 1 |
| Fisher, RS | 1 |
| Pereira, MB | 1 |
| Freitas, RL | 1 |
| Assis, MA | 1 |
| Silva, RF | 1 |
| Takahashi, RN | 1 |
| Jankiewicz, K | 1 |
| Jankiewicz, M | 1 |
| Traa, BS | 1 |
| Mulholland, JD | 1 |
| Kadam, SD | 1 |
| Johnston, MV | 1 |
| Comi, AM | 1 |
| Wolf, SM | 1 |
| Shinnar, S | 1 |
| Kang, H | 1 |
| Gil, KB | 1 |
| Moshé, SL | 2 |
| Krauss, GL | 1 |
| Simmons-O'Brien, E | 1 |
| Campbell, M | 1 |
| Ben-Menachem, E | 1 |
| Söderfelt, B | 1 |
| Hamberger, A | 1 |
| Hedner, T | 1 |
| Persson, LI | 1 |
| Tallian, KB | 1 |
| Nahata, MC | 1 |
| Lo, W | 1 |
| Tsao, CY | 1 |
| Kanthasamy, AG | 1 |
| Vu, TQ | 1 |
| Yun, RJ | 1 |
| Truong, DD | 1 |
| Fernández, MC | 1 |
| Walter, FG | 1 |
| Petersen, LR | 1 |
| Walkotte, SM | 1 |
| Perry, JR | 1 |
| Sawka, C | 1 |
| Haider, A | 1 |
| Tuchek, JM | 1 |
| Haider, S | 1 |
| Cook, LL | 1 |
| Persinger, MA | 1 |
| Nissani, M | 1 |
| Sanchez, EA | 1 |
| Bhaumik, S | 1 |
| Branford, D | 1 |
| Duggirala, C | 1 |
| Ismail, IA | 1 |
| Xiong, ZQ | 1 |
| Stringer, JL | 2 |
| Barron, TF | 1 |
| Hunt, SL | 1 |
| Watson, WP | 1 |
| Robinson, E | 1 |
| Little, HJ | 1 |
| Wilson, EA | 1 |
| Sills, GJ | 1 |
| Forrest, G | 1 |
| Brodie, MJ | 1 |
| Boothe, DM | 1 |
| Mares, P | 1 |
| Haugvicová, R | 1 |
| Welty, TE | 1 |
| Privitera, M | 1 |
| Shukla, R | 1 |
| Lücke, A | 1 |
| Musshoff, U | 1 |
| Köhling, R | 1 |
| Osterfeld, M | 1 |
| Mayer, T | 2 |
| Wolf, P | 2 |
| Schütte, W | 2 |
| Speckmann, EJ | 1 |
| Spagnolo, C | 1 |
| Gareri, P | 1 |
| Gallelli, L | 1 |
| De Sarro, A | 1 |
| Podell, M | 1 |
| Mortimore, C | 1 |
| Trimble, M | 1 |
| Emmers, E | 1 |
| Chadwick, DW | 1 |
| Anhut, H | 1 |
| Greiner, MJ | 1 |
| Alexander, J | 1 |
| Murray, GH | 1 |
| Garofalo, EA | 2 |
| Pierce, MW | 1 |
| Elger, CE | 1 |
| Löscher, W | 2 |
| Reissmüller, E | 1 |
| Ebert, U | 1 |
| Arora, A | 1 |
| Mahajan, V | 1 |
| Cilio, MR | 1 |
| Bolanos, AR | 1 |
| Liu, Z | 1 |
| Schmid, R | 1 |
| Yang, Y | 1 |
| Stafstrom, CE | 1 |
| Mikati, MA | 1 |
| Holmes, GL | 1 |
| DeToledo, JC | 1 |
| Ramsay, RE | 1 |
| Lowe, MR | 1 |
| Greiner, M | 1 |
| Lado, FA | 1 |
| Sperber, EF | 1 |
| Landry, P | 1 |
| Hönack, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.[NCT00537940] | Phase 4 | 482 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis[NCT04511676] | 12 participants (Actual) | Observational | 2018-11-01 | Completed | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The seizures were recorded by the participants, by a family member, by a caregiver, or by a legal guardian and documented in a daily seizure diary. Participant's 28-day seizure frequency of all partial seizure was assessed during double blind (TP + MP) phase compared with baseline. Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + secondary generalized tonic clonic seizure [SGTC]). (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
| Intervention | percent change (Median) |
|---|---|
| Pregabalin | -58.65 |
| Gabapentin | -57.43 |
SGTC Responder is defined as a participant who shows reduction from Baseline to double-blind phase in proportion of 28-Day SGTC Seizure Rate to 28-Day All Partial Seizure Rate. (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
| Intervention | percentage of responders (Number) |
|---|---|
| Pregabalin | 30.8 |
| Gabapentin | 39.8 |
Change in SGTC = (Proportion of SGTC/All Partial Seizure rate during at the double-blind phase) - (Proportion of SGTC/All Partial Seizure rate at Baseline). Negative values indicate reduction from baseline. (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
| Intervention | percentage of all partial seizure/28days (Mean) | |
|---|---|---|
| Baseline (n=114, 114) | Change from Baseline at Double Blind (n=104, 98) | |
| Gabapentin | 59.60 | -2.17 |
| Pregabalin | 56.53 | 1.59 |
HADS: participant rated questionnaire with 2 subscales. Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. (NCT00537940)
Timeframe: Baseline, Week 21
| Intervention | Units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Baseline HADS-A (n=238, 240) | HADS- A Change at Week 21/ET (n=212, 210) | Baseline HADS-D (n=238, 240) | HADS-D Change at Week 21/ET (n=212, 210) | |
| Gabapentin | 7.60 | -0.83 | 5.65 | -0.42 |
| Pregabalin | 7.82 | -0.92 | 5.94 | -0.59 |
Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity (range:0-24), optimal sleep (yes/no), and 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except adequacy, optimal sleep and quantity, higher scores=more impairment. Scores transformed (actual raw score [RS] minus lowest possible score divided by possible RS range*100); total score range:0-100; higher score=more intensity of attribute. (NCT00537940)
Timeframe: Baseline, Week 21
| Intervention | Units on a scale (Least Squares Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Sleep Disturbance (n=238, 240) | Baseline: Snoring (n=238, 240) | Baseline: Awaken Short of Breath (n=238, 240) | Baseline: Quantity of Sleep (n=238, 240) | Baseline: Adequacy of Sleep (n=238, 240) | Baseline: Somnolence (n=238, 240) | Baseline: Sleep Problem Index (9) (n=238, 240) | Week 21: Sleep Disturbance (n=212, 210) | Week 21: Snoring (n=212, 210) | Week 21: Awaken Short of Breath (n=212, 210) | Week 21: Quantity of Sleep (n=212, 210) | Week 21: Adequacy of Sleep (n=212, 210) | Week 21: Somnolence (n=212, 210) | Week 21: Sleep Problem Index (9) (n=212, 210) | |
| Gabapentin | 26.43 | 28.09 | 19.61 | 7.59 | 63.67 | 29.31 | 28.15 | 25.31 | 26.12 | 18.20 | 8.77 | 64.53 | 29.98 | 27.54 |
| Pregabalin | 29.68 | 29.28 | 23.64 | 7.56 | 61.30 | 32.29 | 31.60 | 24.99 | 28.07 | 16.26 | 8.79 | 63.87 | 32.04 | 27.88 |
Participants who had at least 50% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 50% responders. If percent change from baseline <= -50 then responder rate = 1 (yes) otherwise responder rate = 0 (no). (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| All Partial Seizure (n=238, 240) | Simple Partial (n=87, 88) | Complex Partial (n=161, 158) | SGTC (n=112, 114) | |
| Gabapentin | 58.3 | 53.4 | 55.1 | 60.5 |
| Pregabalin | 56.3 | 55.2 | 56.5 | 50.9 |
Participants who had at least 75% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 75% responders. If percent change from baseline <= -75 then 75% responder rate = 1 (yes) otherwise responder rate = 0 (no). Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + SGTC). (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| All Partial Seizure (n=238, 240) | Simple Partial (n=87, 88) | Complex Partial (n=161, 158) | SGTC (n=112, 114) | |
| Gabapentin | 34.2 | 33.0 | 36.1 | 43.9 |
| Pregabalin | 33.6 | 36.8 | 37.3 | 38.4 |
MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Percentage of participants with optimal sleep are reported. (NCT00537940)
Timeframe: Baseline, Week 21
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Baseline (n=238, 240) | Week 21 (n=212, 210) | |
| Gabapentin | 58.8 | 58.6 |
| Pregabalin | 49.2 | 51.4 |
Seizure free for 28 days was defined as participants who have not experienced any seizure (simple partial, complex partial and SGTC) for at least 28 consecutive days from their last seizure until the end of the MP. Same participant could be seizure free for a specific type of seizure but not necessarily for the other types of seizure. (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| All Partial Seizure (n=189, 182) | Simple Partial (n=74, 66) | Complex Partial (n=126, 123) | SGTC (n=95, 91) | |
| Gabapentin | 34.1 | 36.4 | 40.7 | 42.9 |
| Pregabalin | 30.7 | 29.7 | 37.3 | 46.3 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
12 reviews available for gabapentin and Absence Seizure
| Article | Year |
|---|---|
The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches.
Topics: Anticonvulsants; Carbamazepine; Dementia; Epilepsy; Felbamate; Gabapentin; Humans; Inflammasomes; La | 2022 |
Second Generation of Antiepileptic Drugs and Oxidative Stress.
Topics: Anticonvulsants; Carbamazepine; Diazepam; Epilepsy; Epilepsy, Generalized; Fructose; Gabapentin; Hum | 2023 |
Gabapentin monotherapy for epilepsy: A review.
Topics: Anticonvulsants; Carbamazepine; Drug Resistant Epilepsy; Epilepsies, Partial; Epilepsy; Gabapentin; | 2023 |
Pregabalin add-on for drug-resistant focal epilepsy.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, Partial; Gabapentin | 2019 |
Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Topics: Acetamides; Acute Kidney Injury; Amines; Anticonvulsants; Carbamates; Critical Illness; Cyclohexanec | 2016 |
Emergent complications of the newer anticonvulsants.
Topics: Acidosis; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Overdose; Fructo | 2010 |
Cellular and molecular action of the putative GABA-mimetic, gabapentin.
Topics: Acetates; Amines; Analgesics; Animals; Anticonvulsants; Anxiety; Brain; Cyclohexanecarboxylic Acids; | 2003 |
Optimal seizure management in brain tumor patients.
Topics: Amines; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Cyclohexanecarboxylic Acids; Drug I | 2005 |
Seizure control: how to use the new antiepileptic drugs in older patients.
Topics: Acetates; Age Factors; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions | 1996 |
A review of the newer antiepileptic drugs and the ketogenic diet.
Topics: Acetates; Age Factors; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids | 1997 |
Anticonvulsant therapy in small animals.
Topics: Acetates; Amines; Animals; Anticonvulsants; Bromides; Clonazepam; Clorazepate Dipotassium; Cyclohexa | 1998 |
Antiepileptic drug therapy.
Topics: Acetates; Amines; Animals; Anticonvulsants; Bromides; Cat Diseases; Cats; Cyclohexanecarboxylic Acid | 1998 |
11 trials available for gabapentin and Absence Seizure
| Article | Year |
|---|---|
The efficacy of gabapentin in children of partial seizures and the blood levels.
Topics: Adolescent; Age Factors; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Aci | 2014 |
Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Ac | 2016 |
Gabapentin in late-onset poststroke seizures.
Topics: Acetates; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dr | 2002 |
Gabapentin to control seizures in children undergoing cancer treatment.
Topics: Acetates; Amines; Anticonvulsants; Antineoplastic Agents; Brain; Child; Cyclohexanecarboxylic Acids; | 2004 |
Gabapentin toxicity in children manifesting as behavioral changes.
Topics: Acetates; Affect; Aggression; Amines; Anticonvulsants; Behavior; Child; Cyclohexanecarboxylic Acids; | 1995 |
Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Respon | 1995 |
High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Diarrhea; D | 1998 |
Effects of gabapentin on cognition and quality of life in patients with epilepsy.
Topics: Acetates; Adult; Affect; Aged; Amines; Anticonvulsants; Cognition; Cyclohexanecarboxylic Acids; Epil | 1998 |
A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Carbamazepine; Child; | 1998 |
Gabapentin add-on treatment: how many patients become seizure-free? An open-label multicenter study.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; F | 1999 |
Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dose-Response | 2000 |
75 other studies available for gabapentin and Absence Seizure
| Article | Year |
|---|---|
3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase.
Topics: Aminobutyrates; Animals; Anticonvulsants; Enzyme Activation; Glutamate Decarboxylase; Mice; Seizures | 1991 |
Solution-phase parallel synthesis and evaluation of anticonvulsant activity of N-substituted-3,4-dihydroisoquinoline-2(1H)-carboxamides.
Topics: Animals; Anticonvulsants; Isoquinolines; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred DBA; Se | 2009 |
Augmentation of GABAergic neurotransmission by novel N-(substituted)-2-[4-(substituted)benzylidene]hydrazinecarbothioamides-a potential anticonvulsant approach.
Topics: Animals; Anticonvulsants; Electroshock; GABAergic Neurons; Hydrazines; Male; Mice; Mice, Inbred Stra | 2013 |
Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
Topics: Adult; Anticonvulsants; Carbamazepine; Chemical and Drug Induced Liver Injury; Chemical and Drug Ind | 2022 |
Analyzing excipient-related adverse events in antiseizure drug formulations.
Topics: Anticonvulsants; Drug Compounding; Excipients; Gabapentin; Humans; Lamotrigine; Levetiracetam; Seizu | 2022 |
Status Dystonicus with Atypical Presentation in Developmentally Delay Child: A Case Report.
Topics: Baclofen; Child; Child, Preschool; Dystonia; Dystonic Disorders; Female; Gabapentin; Humans; Seizure | 2022 |
Trends in Antiseizure Medication Prescribing Among Nursing Home Residents With and Without a Seizure Diagnosis.
Topics: Anticonvulsants; Databases, Factual; Female; Gabapentin; Humans; Male; Nursing Homes; Retrospective | 2023 |
Psychiatric Comorbidities and Psychiatric Medication Use Are Highly Prevalent in Patients With Eosinophilic Esophagitis and Associate With Clinical Presentation.
Topics: Adolescent; Adult; Age Distribution; Anxiety Disorders; Benzodiazepines; Chest Pain; Child; Chronic | 2020 |
Polygonogram and isobolographic analysis of interactions between various novel antiepileptic drugs in the 6-Hz corneal stimulation-induced seizure model in mice.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Electro | 2020 |
Single step nanospray drying preparation technique of gabapentin-loaded nanoparticles-mediated brain delivery for effective treatment of PTZ-induced seizures.
Topics: Animals; Brain; Chitosan; Drug Carriers; Gabapentin; Nanoparticles; Particle Size; Pentylenetetrazol | 2021 |
Combination therapy of levetiracetam and gabapentin against nonconvulsive seizures induced by penetrating traumatic brain injury.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2017 |
Pregabalin and heart failure: A population-based study.
Topics: Aged; Aged, 80 and over; Amines; Anticonvulsants; Calcium Channel Blockers; Cohort Studies; Cyclohex | 2017 |
Nonlesional late-onset epilepsy: Semiology, EEG, cerebrospinal fluid, and seizure outcome characteristics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Electroencephalography; Epilepsy; Femal | 2019 |
Effects of androsterone on the protective action of various antiepileptic drugs against maximal electroshock-induced seizures in mice.
Topics: Androgens; Androsterone; Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Disease | 2019 |
Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies.
Topics: Animals; Anticonvulsants; Brain; Cannabidiol; Chromatography, High Pressure Liquid; Disease Models, | 2019 |
Oral gabapentin suppresses pentylenetetrazole-induced seizure-like behavior and cephalic field potential in adult zebrafish.
Topics: Action Potentials; Administration, Oral; Amines; Analysis of Variance; Animals; Anticonvulsants; Bra | 2013 |
Combined treatment with gabapentin and drugs affecting the renin-angiotensin system against electroconvulsions in mice.
Topics: Amines; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2013 |
[Comparison of neuroprotective effects of anticonvulsant drugs in brain injury therapy].
Topics: Amines; Animals; Animals, Outbred Strains; Anticonvulsants; Brain; Brain Injuries; Brain Ischemia; C | 2012 |
Gabapentin administration reduces reactive gliosis and neurodegeneration after pilocarpine-induced status epilepticus.
Topics: Amines; Animals; Astrocytes; Cyclohexanecarboxylic Acids; Electroencephalography; Gabapentin; gamma- | 2013 |
Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies.
Topics: Amines; Animals; Anticonvulsants; Brain; Cyclohexanecarboxylic Acids; Disease Models, Animal; Drug C | 2014 |
Effects of intravenous human umbilical cord blood mesenchymal stem cell therapy versus gabapentin in pentylenetetrazole-induced chronic epilepsy in rats.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Epilepsy; Female; Gabapentin; | 2014 |
Influence of caffeine on the protective activity of gabapentin and topiramate in a mouse model of generalized tonic-clonic seizures.
Topics: Amines; Animals; Anticonvulsants; Caffeine; Cyclohexanecarboxylic Acids; Dose-Response Relationship, | 2016 |
Protective effects of gabapentin against the seizure susceptibility and comorbid behavioral abnormalities in the early socially isolated mice.
Topics: Aggression; Amines; Animals; Anticonvulsants; Anxiety; Behavior, Animal; Comorbidity; Cyclohexanecar | 2017 |
Gabapentin-Induced Bullous Pemphigoid.
Topics: Aged, 80 and over; Amines; Biopsy, Needle; Cyclohexanecarboxylic Acids; Follow-Up Studies; Gabapenti | 2017 |
Tramadol-induced seizurogenic effect: a possible role of opioid-dependent gamma-aminobutyric acid inhibitory pathway.
Topics: Amines; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; GABA Agents; Gabapentin; gamma-Ami | 2008 |
Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Brain; Cyclohexanecarboxylic Acids; Disease Mode | 2008 |
[Paroxysmal kinesigenic dyskinesia: a channelopathy? Study of 19 cases].
Topics: Adolescent; Adult; Age of Onset; Amines; Anticonvulsants; Channelopathies; Child; Child, Preschool; | 2009 |
Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis.
Topics: Amines; Animals; Anticonvulsants; Brain; Cyclohexanecarboxylic Acids; Disease Models, Animal; Drug I | 2009 |
Effect of gabapentin on cognitive processes in rats not exposed and exposed to tobacco smoke during fetal life.
Topics: Amines; Animals; Anticonvulsants; Antidepressive Agents; Behavior, Animal; Cognition; Cyclohexanecar | 2008 |
Antiepileptic drugs combined with high-frequency electrical stimulation in the ventral hippocampus modify pilocarpine-induced status epilepticus in rats.
Topics: Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Disease Models, Animal; Electric Stim | 2010 |
Amisulpride-induced seizurogenic effect: a potential role of opioid receptor-linked transduction systems.
Topics: Amines; Amisulpride; Analysis of Variance; Animals; Anti-Asthmatic Agents; Cromolyn Sodium; Cyclohex | 2011 |
Effect of combined treatment of thioperamide with some antiepileptic drugs on methionine-sulfoximine induced convulsions in mice.
Topics: Amines; Animals; Anticonvulsants; Brain; Cyclohexanecarboxylic Acids; Drug Combinations; Gabapentin; | 2010 |
Performance characteristics of the ARK diagnostics gabapentin immunoassay.
Topics: Amines; Anticonvulsants; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Cyclohexanec | 2011 |
Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis.
Topics: Amines; Animals; Anticonvulsants; Avoidance Learning; Confidence Intervals; Cyclohexanecarboxylic Ac | 2012 |
Influence of carvedilol on anticonvulsant effect of gabapentin.
Topics: Amines; Analysis of Variance; Animals; Anticonvulsants; Brain; Carbazoles; Carvedilol; Convulsants; | 2011 |
Sildenafil influences the anticonvulsant activity of vigabatrin and gabapentin in the timed pentylenetetrazole infusion test in mice.
Topics: Amines; Animals; Anticonvulsants; Avoidance Learning; Cyclohexanecarboxylic Acids; Disease Models, A | 2012 |
Antiepileptic drugs prevent changes in adenosine deamination during acute seizure episodes in adult zebrafish.
Topics: Adenine Nucleotides; Adenosine; Adenosine Deaminase; Amines; Animals; Anticonvulsants; Brain; Cycloh | 2013 |
Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis.
Topics: Acetates; Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease M | 2002 |
Long-term regulation of voltage-gated Ca(2+) channels by gabapentin.
Topics: Acetates; Amines; Animals; Anticonvulsants; Brain; Calcium Channels, P-Type; Calcium Channels, Q-Typ | 2002 |
Coadministration of gabapentin or MK-801 with lamotrigine slows tolerance to its anticonvulsant effects on kindled seizures.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Dizocilpine Maleate; Drug T | 2003 |
Treatment with the antiepileptic drugs phenytoin and gabapentin ameliorates seizure and paralysis of Drosophila bang-sensitive mutants.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, | 2004 |
Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study.
Topics: Amines; Animals; Anticonvulsants; Convulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationsh | 2004 |
Antiepileptic drug treatment of nonconvulsive seizures induced by experimental focal brain ischemia.
Topics: Amines; Animals; Anticonvulsants; Brain Infarction; Brain Injuries; Brain Ischemia; Cyclohexanecarbo | 2004 |
Synergistic interaction of gabapentin and oxcarbazepine in the mouse maximal electroshock seizure model--an isobolographic analysis.
Topics: Amines; Animals; Anticonvulsants; Brain; Carbamazepine; Cyclohexanecarboxylic Acids; Disease Models, | 2005 |
Isobolographic characterisation of interactions among selected newer antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model.
Topics: Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Disease Models, Animal | 2005 |
Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent.
Topics: Amines; Animals; Anticonvulsants; Bromides; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Dog | 2005 |
Evaluation of gabapentin and ethosuximide for treatment of acute nonconvulsive seizures following ischemic brain injury in rats.
Topics: Acute Disease; Amines; Animals; Brain Ischemia; Cyclohexanecarboxylic Acids; Dose-Response Relations | 2006 |
Effect of gabaergic, glutamatergic, antipsychotic and antidepressant drugs on pilocarpine-induced seizures and status epilepticus.
Topics: Amines; Amitriptyline; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2006 |
Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Brain; Brain Chemistry; Cyclohexanecarboxylic Ac | 2007 |
Intraventricular administration of gabapentin in the rat increases flurothyl seizure threshold.
Topics: Amines; Animals; Anticonvulsants; Brain; Brain Chemistry; Cerebral Cortex; Convulsants; Cyclohexanec | 2007 |
Study pharmacologic of the GABAergic and glutamatergic drugs on seizures and status epilepticus induced by pilocarpine in adult Wistar rats.
Topics: Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Ga | 2007 |
Influence of aminophylline on the anticonvulsive action of gabapentin in the mouse maximal electroshock seizure threshold model.
Topics: Amines; Aminophylline; Animals; Anticonvulsants; Brain; Brain Chemistry; Bronchodilator Agents; Chro | 2007 |
Gabapentin neuroprotection and seizure suppression in immature mouse brain ischemia.
Topics: Amines; Animals; Animals, Newborn; Anticonvulsants; Atrophy; Behavior, Animal; Body Temperature; Bra | 2008 |
Gabapentin--a new antiepileptic drug.
Topics: Acetates; Aged; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Ami | 1994 |
Successful treatment of seizures and porphyria with gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyr | 1995 |
Gabapentin associated with aggressive behavior in pediatric patients with seizures.
Topics: Acetates; Adolescent; Age Factors; Aggression; Amines; Anticonvulsants; Child; Child Behavior Disord | 1996 |
Antimyoclonic effect of gabapentin in a posthypoxic animal model of myoclonus.
Topics: Acetates; Acoustic Stimulation; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; DDT; | 1996 |
Gabapentin, valproic acid, and ethanol intoxication: elevated blood levels with mild clinical effects.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions; Drug Overd | 1996 |
Add-on gabapentin for refractory seizures in patients with brain tumours.
Topics: Acetates; Amines; Anticonvulsants; Brain Neoplasms; Cyclohexanecarboxylic Acids; Follow-Up Studies; | 1996 |
Long-term consequences of subtle stimuli during the first twenty-four hours of seizure-induced brain injury.
Topics: Acetates; Amines; Animals; Anticonvulsants; Appetitive Behavior; Brain Damage, Chronic; Cholinergic | 1996 |
Stuttering caused by gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyr | 1997 |
A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Dose-Respo | 1997 |
Effects of felbamate, gabapentin and lamotrigine on seizure parameters and excitability in the rat hippocampus.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, | 1997 |
The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome.
Topics: Acetates; Amines; Animals; Anticonvulsants; Ataxia; Behavior, Animal; Cyclohexanecarboxylic Acids; E | 1997 |
Anticonvulsant action of gabapentin during postnatal development in rats.
Topics: Acetates; Amines; Animals; Anticonvulsants; Behavior, Animal; Brain; Cyclohexanecarboxylic Acids; Do | 1997 |
Increased seizure frequency associated with felbamate withdrawal in adults.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Felbamate; Gabapentin; gamma- | 1998 |
Gabapentin potentiation of the antiepileptic efficacy of vigabatrin in an in vitro model of epilepsy.
Topics: 4-Aminobutyrate Transaminase; Acetates; Amines; Animals; Anticonvulsants; Bicuculline; Cyclohexaneca | 1998 |
Gabapentin potentiates the antiseizure activity of certain anticonvulsants in DBA/2 mice.
Topics: Acetates; Acoustic Stimulation; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug | 1998 |
Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Evaluation; Drug Resis | 2000 |
Gabapentin in seizures due to acute intermittent porphyria.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami | 2000 |
The effects of gabapentin in the rat hippocampus are mimicked by two structural analogs, but not by nimodipine.
Topics: Acetates; Amines; Animals; Anticonvulsants; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; C | 2000 |
Anticonvulsant action and long-term effects of gabapentin in the immature brain.
Topics: Acetates; Amines; Animals; Anticonvulsants; Behavior, Animal; Brain; Convulsants; Cyclohexanecarboxy | 2001 |
Anticonvulsant efficacy of gabapentin on kindling in the immature brain.
Topics: Acetates; Age Factors; Amines; Amygdala; Animals; Anticonvulsants; Behavior, Animal; Brain; Child; C | 2001 |
Gabapentin for clozapine-related seizures.
Topics: Acetates; Aged; Amines; Antimanic Agents; Antipsychotic Agents; Clozapine; Cyclohexanecarboxylic Aci | 2001 |
Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain.
Topics: Acetates; Amines; Aminooxyacetic Acid; Animals; Anticonvulsants; Brain Chemistry; Cyclohexanecarboxy | 1991 |